Strong Tower Advisory Services Increases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Strong Tower Advisory Services boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 22,108 shares of the company’s stock after acquiring an additional 267 shares during the quarter. Novo Nordisk A/S accounts for about 1.0% of Strong Tower Advisory Services’ portfolio, making the stock its 25th biggest holding. Strong Tower Advisory Services’ holdings in Novo Nordisk A/S were worth $2,287,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacific Center for Financial Services lifted its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Copeland Capital Management LLC raised its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after acquiring an additional 141 shares in the last quarter. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. Citizens National Bank Trust Department raised its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after purchasing an additional 150 shares during the last quarter. Finally, Tyler Stone Wealth Management increased its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of several research reports. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, March 20th. Finally, TD Cowen lifted their target price on Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, December 4th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.25.

Novo Nordisk A/S Stock Up 0.3 %

NYSE NVO opened at $128.40 on Friday. The firm has a 50-day simple moving average of $121.76 and a 200 day simple moving average of $104.38. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The stock has a market cap of $576.20 billion, a PE ratio of 47.47, a PEG ratio of 2.11 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.35 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th will be issued a $0.664 dividend. The ex-dividend date is Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.